Anti-VEGF Use in Ophthalmology
1st Edition
Published on 15. May 2017
Book
Paperback/Softback
238 pages
978-1-63091-321-2 (ISBN)
Description
The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions.
Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use.
The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents.
Some of the topics covered in Anti-VEGF Use in Ophthalmology:
Neovascular Age-Related Macular Degeneration
Proliferative Diabetic Retinopathy
Retinal Vein Occlusion
Uveitis
Neovascular Glaucoma
Macular Edema
Retinopathy of Prematurity
Corneal Disease
Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.
Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use.
The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents.
Some of the topics covered in Anti-VEGF Use in Ophthalmology:
Neovascular Age-Related Macular Degeneration
Proliferative Diabetic Retinopathy
Retinal Vein Occlusion
Uveitis
Neovascular Glaucoma
Macular Edema
Retinopathy of Prematurity
Corneal Disease
Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.
More details
Language
English
Place of publication
Thorofare
United States
Target group
Professional and scholarly
Professional Practice & Development
Dimensions
Height: 229 mm
Width: 152 mm
Thickness: 14 mm
Weight
354 gr
ISBN-13
978-1-63091-321-2 (9781630913212)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Jay Duker | Michelle Liang
Anti-VEGF Use in Ophthalmology
E-Book
06/2024
1st Edition
CRC Press
€158.99
Available for download
Jay Duker | Michelle Liang
Anti-VEGF Use in Ophthalmology
E-Book
06/2024
1st Edition
CRC Press
€158.99
Available for download
Persons
Jay S. Duker, MD, is Professor and Chairman of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine and Director of the New England Eye Center in Boston, Massachusetts. Dr. Duker graduated from Jefferson Medical College and completed ophthalmology and retina training at the Wills Eye Hospital. His research and clinical interests are focused on the posterior segment ranging from macular degeneration, diabetic retinopathy, and retinal vascular diseases, as well as uveitis and intraocular tumors. He has published more than 280 journal articles and has been lead editor on six books and dozens of book chapters. Dr. Duker is the co-editor of the International Journal of Retina and Vitreous.
Michelle C. Liang, MD, is Assistant Professor of Ophthalmology at the Tufts University School of Medicine and a vitreoretinal specialist at the New England Eye Center in Boston, Massachusetts. She graduated with honors from Johns Hopkins University with a degree in Biology and earned her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences. She performed her residency in ophthalmology at the New England Eye Center at Tufts Medical Center and went on to complete a vitreoretinal surgery fellowship at the New England Eye Center and Ophthalmic Consultants of Boston.
Dr. Liang has authored numerous scientific papers and book chapters and has presented at several national meetings. She treats all conditions of the retina and vitreous, including macular degeneration, vitreomacular disorders, diabetic retinopathy, retinal vascular disorders, retinal detachment, and cataract complications. Her research interests include retinal imaging and new therapies for macular degeneration, diabetic macular edema, and other diseases. Dr. Liang is a board-certified member of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology and American Society of Retinal Specialists.
Michelle C. Liang, MD, is Assistant Professor of Ophthalmology at the Tufts University School of Medicine and a vitreoretinal specialist at the New England Eye Center in Boston, Massachusetts. She graduated with honors from Johns Hopkins University with a degree in Biology and earned her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences. She performed her residency in ophthalmology at the New England Eye Center at Tufts Medical Center and went on to complete a vitreoretinal surgery fellowship at the New England Eye Center and Ophthalmic Consultants of Boston.
Dr. Liang has authored numerous scientific papers and book chapters and has presented at several national meetings. She treats all conditions of the retina and vitreous, including macular degeneration, vitreomacular disorders, diabetic retinopathy, retinal vascular disorders, retinal detachment, and cataract complications. Her research interests include retinal imaging and new therapies for macular degeneration, diabetic macular edema, and other diseases. Dr. Liang is a board-certified member of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology and American Society of Retinal Specialists.
Content
Dedication About the Editors Contributing AuthorsIntroduction Section I Overview of Anti-Vascular Endothelial Growth Factor Agents Chapter 1 Vascular Endothelial Growth Factor: Background and HistoryAnthony Joseph, MD and Ehsan Rahimy, MD Chapter 2 Development of Anti-Vascular Endothelial Growth Factor AgentsMaya H. Maloney, MD and Sophie J. Bakri, MD Chapter 3 Available Anti-Vascular Endothelial Growth Factor AgentsAngeline Mariani Derham, MD and David M. Brown, MD, FACS Chapter 4 Agents Under Study Ehsan Rahimy, MD; Elham Rahimy, BS; and Anthony Joseph, MD Chapter 5 Intravitreal DeliveryNora Muakkassa, MD; Kendra Klein, MD; and Elias Reichel, MD Chapter 6 Sustained Delivery Options Under StudyMichael N. Cohen, MD; Chirag P. Shah, MD, MPH; and Jeffrey S. Heier, MD Section II Use of Anti-Vascular Endothelial Growth Factor Agents in Clinical Practice Chapter 7 Neovascular Age-Related Macular DegenerationMichael D. Lewen, MD and Andre J. Witkin, MD Chapter 8 Choroidal Neovascularization, Not Age-Related Macular DegenerationDarin R. Goldman, MD Chapter 9 Diabetic Macular EdemaEmily D. Cole, BS; Eduardo A. Novais MD; and Nadia K. Waheed, MD, MPH Chapter 10 Proliferative Diabetic RetinopathySabin Dang, MD and Chirag P. Shah, MD, MPH Chapter 11 Retinal Vein OcclusionShilpa Desai, MD and Caroline R. Baumal, MD Chapter 12 UveitisLana M. Rifkin, MD Chapter 13 Retinopathy of PrematurityNikisha A. Kothari, MD and Audina M. Berrocal, MD Chapter 14 Miscellaneous Retinal and Choroidal DiseasesMichael D. Tibbetts, MD Chapter 15 Neovascular GlaucomaManik Goel, MD and Joel S. Schuman, MD, FACS Chapter 16 Glaucoma SurgeryJessica J. Moon, MD and Cynthia Mattox, MD Chapter 17 Anterior Segment DiseasesAlessandro Abbouda, MD; Bijan Khaksari, BA; and Pedram Hamrah, MD, FRCSFinancial Disclosures Index